RDHL Stock Analysis: Buy, Sell, or Hold?
RDHL - Redhill Biopharma Ltd.
$0.81
0.03 (3.67%)
▲
5d:
-11.64%
30d:
-12.32%
90d:
-8.34%
WAIT
LOW Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Apr 09, 2026
0d
Get Alerted When RDHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RDHL is down 11.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RDHL is down 11.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RDHL is currently trading at $0.81, which is considered oversold relative to its 30-day fair value range of $0.86 to $1.03.
Technical Outlook: Technically, RDHL is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: RDHL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2334626.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDHL is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: RDHL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2334626.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.86 -
$1.03
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 2334626.0% below Wall St target ($19000.00)
- WARNING: Recommendation downgraded due to -11.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.86 -
$1.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.09
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1428.57
Wall Street Target
$19000.00
(+2334626.0%)
Revenue Growth (YoY)
58.6%
Profit Margin
-150.0%
Share & Embed Analysis
Last updated: June 21, 2026 1:23 PM ET
Data refreshes hourly during market hours. Next update: 2:23 PM
Data refreshes hourly during market hours. Next update: 2:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilead Raday
SELL
15740000 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 58 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
